The disruption of RBM39 leads to abnormal splicing events and altered gene expression, impacting cell cycle progression and promoting tumor regression.300 E7820, targets RBM39 and its homologous protein RBM32 for degradation via the DCAF15 E3 ubiquitin ligase pathway, displaying cytotoxic effects across various cancer cell lines.301 Despite sharing myelosuppressive side effects similar to Indisulam, E7820 offers improved oral bioavailability. The gene discussed is RBM39; the disease is neoplasm.